Clinical applications of biomarkers in preeclampsia

Melanie Griffin, Andrew H. Shennan*

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

9 Citations (Scopus)

Abstract

Preeclampsia remains a significant cause of maternal morbidity and mortality worldwide. Prediction, diagnosis and management continue to be challenging but advances in the understanding of the pathophysiological processes underlying the disease has enabled identification of multiple biomarkers, some of which aid prediction of those at risk. Even in isolation, some of these biomarkers have demonstrated sufficient test performance for incorporation into clinical practice. A combination of the most promising biomarkers and clinical factors may improve risk prediction, and aid diagnosis and subsequent management through development of integrated clinical risk models. This article aims to review the literature relating to biomarkers in preeclampsia and summarize the possible clinical applications of these findings.

Original languageEnglish
Pages (from-to)459-470
Number of pages12
JournalBiomarkers in Medicine
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 2014

Keywords

  • biomarkers
  • clinical
  • diagnosis
  • disease
  • management
  • prediction
  • preeclampsia
  • screening
  • PLACENTAL GROWTH-FACTOR
  • UTERINE ARTERY DOPPLER
  • SUBSEQUENTLY DEVELOP PREECLAMPSIA
  • GELATINASE-ASSOCIATED LIPOCALIN
  • MATERNAL PLASMA-CONCENTRATIONS
  • HUMAN CHORIONIC-GONADOTROPIN
  • EARLY-ONSET PREECLAMPSIA
  • ANGIOGENIC FACTORS
  • SOLUBLE ENDOGLIN
  • WEEKS GESTATION

Fingerprint

Dive into the research topics of 'Clinical applications of biomarkers in preeclampsia'. Together they form a unique fingerprint.

Cite this